Aims/hypothesis 'Glucotoxicity' is a term used to convey the negative effect of hyperglycaemia on beta cell function; however, the underlying molecular mechanisms that impair insulin secretion and gene expression are poorly defined. Our objective was to define the role of transcription factor v-ets avian erythroblastosis virus E26 oncogene homologue 1 (Ets-1) in beta cell glucotoxicity. Methods Primary islets and Min6 cells were exposed to high glucose and Ets-1 expression was measured. Recombinant adenovirus and transgenic mice were used to upregulate Ets-1 expression in beta cells in vitro and in vivo, and insulin secretion was assessed. The binding activity of H3/H4 histone on the Ets-1 promoter, and that of forkhead box (FOX)A2, FOXO1 and Ets-1 on the Pdx-1 promoter was measured by chromatin immunoprecipitation and quantitative real-time PCR assay. Results High glucose induced upregulation of Ets-1 expression and hyperacetylation of histone H3 and H4 at the Ets-1 gene promoter in beta cells. Ets-1 overexpression dramatically suppressed insulin secretion and biosynthesis both in vivo and in vitro. Besides, Ets-1 overexpression increased the activity of FOXO1 but decreased that of FOXA2 binding to the pancreatic and duodenal homeobox 1 (PDX-1) homology region 2 (PH2), resulting in inhibition of Pdx-1 promoter activity and downregulation of PDX-1 expression and activity. In addition, high glucose promoted the interaction of Ets-1 and FOXO1, and the activity of Ets-1 binding to the Pdx-1 promoter. Importantly, PDX-1 overexpression reversed the defect in pancreatic beta cells induced by Ets-1 excess, while knockdown of Ets-1 prevented hyperglycaemia-induced dysfunction of pancreatic beta cells. Conclusions/interpretation Our observations suggest that Ets-1 links glucotoxicity to pancreatic beta cell dysfunction through inhibiting PDX-1 expression in type 2 diabetes.
Introduction
Under physiological conditions, pancreatic beta cells modulate insulin secretion to maintain blood glucose in the normal range [1] . Diabetes mellitus occurs when beta cells fail to maintain adequate insulin production to prevent hyperglycaemia. Currently, intrinsic beta cell dysfunction and decreased functional beta cell mass are thought to be two important components of diabetic beta cell failure [2] . Results from studies in db/db mice, the partial pancreatectomy rats and ZDF rats revealed that chronic hyperglycaemia, commonly called 'glucotoxicity', is a major determinant of causing beta cell failure [3] [4] [5] . Several complex mechanisms are involved in beta cell glucotoxicity, including beta cell overstimulation, oxidative stress, endoplasmic reticulum stress, hypoxic stress and protein glycation [6] . Among these, O-GlcNAc modification of transcription factors such as pancreatic and duodenal homeobox 1 (PDX-1), neurogenic differentiation 1 (NeuroD1), SP1 and p53 might play a key role in glucotoxicity [7] .
PDX-1, which is expressed in beta cells and few delta cells of the adult islet of Langerhans, is a master regulator of beta cell growth and function [8] . PDX-1 regulates the expression of islet-specific genes through its interaction with their promoter regions, which include insulin, GLUT2, glucokinase (GCK), islet amyloid polypeptide (IAPP), somatostatin and PDX-1 itself [9] [10] [11] [12] [13] [14] . Clinically, mutations in PDX-1 cause MODY4 and later-onset type 2 diabetes mellitus [15, 16] . In mice, selective inactivation of PDX-1 in beta cells leads to the development of diabetes with increasing age [3] . In addition, chronic hyperglycaemia causes loss of beta cell function by reducing PDX-1 expression and DNA binding activities [17] .
Forkhead box (FOX)O1 is a transcription factor that negatively regulates PDX-1 expression and has also been implicated in beta cell glucotoxicity [18, 19] . FOXO1 inhibits PDX-1 expression by binding to the PDX-1 homology region 2 (PH2) of the PDX-1 promoter, which contains a FOXA2 binding site [18, 20] . As a multifunctional protein, FOXO1 regulates beta cell function, proliferation, differentiation and apoptosis [21] . Asada et al demonstrated that FOXO1 could interact with transcription factor v-ets avian erythroblastosis virus E26 oncogene homologue 1 (Ets-1) in bovine carotid artery endothelial cells, which we have also demonstrated in pancreatic beta cells [22] . As a result, Ets-1 might be involved in regulation of beta cell failure in diabetes mellitus.
In recent years, evidence has confirmed that the acetylation status of histones has been shown to be important in pancreatic beta cell function [23] . Histone acetylation promotes gene expression by increasing the approachability of promoters to the transcription machinery [24] . We found that transcription factor Ets-1 was significantly upregulated in high glucosetreated primary islets and Min6 cells as well as isolated islets from db/db mice. We also found the histone deacetylase inhibitor could upregulate Ets-1 expression in pancreatic beta cells. We hypothesised that epigenetic modification might be involved in regulation of Ets-1 expression in high glucosetreated beta cells. Our research group tested this hypothesis using the pancreatic beta cell line Min6, primary islets and transgenic mice that overexpress Ets-1.
Methods
Reagents See Electronic Supplementary Material (ESM) Methods.
Cell culture Mouse Min6 and rat RINm5F cell lines were established as described previously [25, 26] . See ESM Methods.
Islet isolation and culture Male wild-type C57BL/BKS mice and mice functionally deficient for the long-form leptin receptor (db/db mice) were obtained from Nanjing University, China. Male 8-week-old Sprague-Dawley rats were purchased from Nanjing Medical University Laboratory Animal Centre, Nanjing, China. Islet isolation and culturing techniques were described previously [27] . See ESM Methods.
RNA interference, plasmid and recombinant adenoviruses construction The Ets-1 expression plasmid used was as previously described [26] . Ets-1 overexpression adenovirus (AdEts-1), PDX-1 overexpression adenovirus (Ad-Pdx-1) and small interfering (RNA)-Ets-1 adenovirus (si-Ets-1) were constructed and purified as previously described [28] . See ESM Methods.
Glucose-stimulated insulin secretion assay and insulin content extraction Glucose-stimulated insulin secretion assays and insulin content extraction in Min6 cells and isolated islets were performed as previously reported [27] . See ESM Methods.
Real-time PCR Total RNA was extracted from Min6 cells, RINm5F cells and isolated islets. Real-time PCR was used to determine the relative expression levels of mRNAs. See ESM Methods.
Western blot analysis Total protein was isolated from Min6 cells, RINm5F cells and isolated islets. Western blotting was performed as described [29] . See ESM Methods.
Transient transfection and luciferase reporter assay The plasmids were transfected into RINm5F cells. Transient transfections and luciferase reporter assays were performed as described [30] . See ESM Methods.
Electron microscopy analysis Islets were fixed in 2.5% (vol./ vol.) glutaraldehyde and embedded in Lowicryl K4M resin. See ESM Methods.
Chromatin immunoprecipitation and chromatin immunoprecipitation-quantitative PCR assay Chromatin immunoprecipitation (ChIP) and ChIP-quantitative-PCR (ChIP-qPCR) assays were performed using lysates of Min6 and RINm5F cells as described previously [31] . See ESM Methods.
Immunoprecipitation assay Immunoprecipitation (IP) assays were performed using extracts of RINm5F cells as described previously [32] . See ESM Methods.
Generation of Ets-1 transgenic mice Ets-1 overexpression in beta cells of transgenic mice (C57BL/6J strain) was constructed (Model Animal Research Centre, Nanjing University, Nanjing, China) as described previously [33, 34] . Founder mice were identified by PCR of tail biopsies using two pairs of primers (ESM Table 1 ). Heterozygous transgenic mice were used throughout the present studies and non-transgenic littermates were used as controls. We studied 3-to 12-week-old male mice. All animals had free access to standard mouse chow and water, and were housed in a temperaturecontrolled facility with a 12 h light/dark cycle. All animal studies were performed according to guidelines established by the Research Animal Care Committee of Nanjing Medical University, China (Permit Number: IACUC-NJMU 1404075). The experimenters were not blind to group assignment and outcome assessment.
i.p. glucose tolerance test and insulin tolerance test in mice At 8 weeks of age, control mice and transgenic mice were randomised to perform i.p. glucose tolerance tests and insulin tolerance tests [35] . See ESM Methods.
Statistical analysis Comparisons were performed using Student's t test between two groups or ANOVA in multiple groups. Results are presented as means±SD. A p value of <0.05 was considered to be statistically significant. Results are representative of three individual experiments. No data, samples or animals were excluded or omitted from reporting.
Results
Ets-1 expression is elevated in db/db mice islets and in pancreatic beta cells exposed to hyperglycaemia Although Ets-1 was reported to be related to pancreatic development [36] , few studies have investigated its expression in pancreatic islets. We compared Ets-1 gene expression in pancreatic islets from 8-week-old db/db and control C57BL/BKS mice. Our results showed that Ets-1 mRNA and protein level was significantly increased in islets from db/db mice compared with control C57BL/BKS mice (Fig. 1a,b) . Moreover, high glucose increased Ets-1 expression and Ets-1 protein level in Min6 cells, and isolated mouse and rat islets (Fig. 1c-f ).
High glucose mediates hyperacetylation of histone H3 and H4 at the Ets-1 gene promoter To explore whether high glucose induced upregulation of Ets-1 expression by causing hyperacetylation of histone, we treated Min6 cells with different concentrations of the histone deacetylase inhibitor trichostatin A (TSA). We observed that TSA significantly upregulated Ets-1 expression both in mRNA and protein levels (Fig. 2a,b) . Then, we performed a ChIP-qPCR assay to measure whether high glucose mediated hyperacetylation of histone at the Ets-1 gene promoter. Exposure of Min6 cells to high concentrations of glucose for 48 h led to ∼12.5-fold increase in histone H4 acetylation and a sixfold increase in histone H3 acetylation (Fig. 2c,d ).
Overexpression of Ets-1 impairs insulin secretion and synthesis in vitro and in vivo The finding that Ets-1 expression was significantly increased by high glucose prompted us to investigate the effect of Ets-1 on insulin secretion in Min6 cells and isolated primary mouse islets. Overexpression of Ets-1 in Min6 cells and islets significantly inhibited the glucose-stimulated index (GSI), which reflects the insulin secretion ratio of pancreatic beta cells stimulated by high and low glucose (Fig. 3a,b and ESM Fig. 1 ). Similar results for insulin content were obtained (Fig. 3c,d ). Moreover, insulin secretion under high glucose, normalised to insulin content, was also repressed after overexpressing Ets-1 (Fig. 3e,f) .
To investigate whether Ets-1 overexpression could impair insulin secretion in vivo, we next measured the effect of Ets-1 on pancreatic beta cell function using a transgenic mice (line 107) expressing the Ets-1 gene directed by an insulin promoter [37] . Immunofluorescent staining of islets revealed Ets-1 was specifically overexpressed in pancreatic beta cells and there was a distinct inverse relationship between Ets-1 and insulin protein levels (ESM Fig. 2a ). Islet electron microscopy showed a decrease in the number of insulin secretory granules in transgenic mice compared with control mice (Fig. 3g ). In addition, Ets-1 expression was unaffected in nonpancreatic tissues, including spleen and liver (ESM Fig. 2b ).
The transgenic mice were born at the expected Mendelian ratio and maintained normal weight through our 12-week observational period (ESM Fig. 2c) ; however, they displayed fasting hyperglycaemia starting at 7 weeks of age (Fig. 3h) . Besides, blood glucose levels of transgenic mice were higher at every time point after intravenous glucose loading (1.5 g/kg body weight [BW]) compared with wild-type controls (Fig. 3i ). In addition, plasma insulin levels of transgenic mice were lower at every time point after intravenous glucose loading (3 g/kg BW) compared with littermate controls (Fig. 3j) . However, peripheral glucose uptake was not significantly different between transgenic mice and control mice (Fig. 3k ). This result indicated that the glucose intolerance of Ets-1 transgenic mice was due to defective insulin secretion but not insulin resistance. It is important to note that we also obtained three transgenic lines exhibiting high (line 107), medium (line 123) and low (line 79) levels of Ets-1 expression in islets. Both line 123 and line 79 displayed defective insulin secretion (ESM Fig. 2d-g ).
Ets-1 overexpression exerts a suppressive effect on PDX-1 expression by inhibiting PDX-1 promoter activity To evaluate the possible implications of Ets-1 overexpression for beta cell dysfunction, we examined the effects of Ets-1 on beta cellassociated gene expression. As shown in Fig. 4a ,b, the amount of Pdx-1 mRNA was remarkably decreased in the Ets-1-overexpressing Min6 and RINm5F cells, whereas the expression levels of Neurod1, Mafa and Foxa2 were unchanged. Furthermore, Ets-1 overexpression led to similar reduction of PDX-1 protein in Min6 and RINm5F cells. The expression of PDX-1 in islets of transgenic mice was also significantly decreased compared with littermate control islets (Fig. 4c) . Therefore, the expression of PDX-1 in vivo and in vitro was inhibited by Ets-1 overexpression. Next, we determined the mRNA levels of insulin and Gck, which are both directly regulated by PDX-1, to explore whether Ets-1 had an effect on PDX-1 transcriptional activity. ChIP-qPCR assay confirmed that DNA fragments pulled down by an anti-PDX antibody in the Ets-1 overexpressing cells were reduced to approximately 0.6-fold for the insulin promoter site and 0.55-fold for the Gck promoter site (Fig. 4d) .
Further study showed that Ets-1 could bind to the PH2 region of the Pdx-1 promoter, which was the common DNA binding site of FOXO1 and FOXA2 (Fig. 4e) . To investigate whether Ets-1 overexpression could affect the activity of FOXA2 and FOXO1 on the Pdx-1 promoters, a ChIP-qPCR assay was performed. As shown in Fig. 4f , DNA fragments pulled down by the anti-FOXA2 antibody in the Ets-1 overexpression group were reduced to approximately 0.46-fold for the PH2 region of the Pdx-1 promoter. However, the effect of Ets-1 overexpression on activity of FOXO1 binding to the PH2 region was elevated up to 2.05-fold (Fig. 4g) . Additionally, in Ets-1 overexpression groups, DNA fragments pulled down by the anti-Ets-1 antibody were increased to twofold (Fig. 4h) . More importantly, Ets-1 overexpression significantly decreased Pdx-1 promoter activity (Fig. 4i) . PDX-1 and Ets-1 were both overexpressed (Fig. 5a ). Insulin secretion was reduced to 60% in Min6 cells treated with Ets-1 overexpression alone, while restored to 85% by cooverexpression of Ets-1 and PDX-1 (Fig. 5b) . Besides, PDX-1 overexpression reversed the decrease of insulin content, and insulin secretion, under high glucose that was normalised to insulin content in Min6 cells overexpressing Ets-1 (Fig. 5c,d ).
Hyperglycaemia promotes the interaction of Ets-1 and FOXO1, and the activity of Ets-1 binding to the Pdx-1 promoter To explore whether high glucose promotes the interaction of Ets-1 and FOXO1, we performed an IP assay. As shown in Fig. 6a , endogenous interaction of Ets-1 and FOXO1 was significantly increased in RINm5F cells treated with high glucose for 48 h. Next, we performed a ChIP-qPCR assay to measure the activity of Ets-1 binding to the Pdx-1 promoter in high glucose-treated RINm5F cells. DNA fragments pulled down by the anti-Ets-1 antibody in the high glucose-treated group were increased to approximately 2.1-fold for the Pdx-1 promoter (Fig. 6b) .
Inhibition of Ets-1 reverses hyperglycaemia-induced beta cell failure Using the recombinant adenoviruses for knockdown of Ets-1 expression (si-Ets-1), we next analysed the effect of Ets-1 downregulation on glucose-stimulated insulin secretion (GSIS) and insulin content in isolated islets, and Min6 cells treated with high glucose for 72 h. As demonstrated, si-Ets-1 effectively silenced Ets-1 gene expression and coordinately increased PDX-1 protein level in high glucose (Fig. 7a) . Knockdown of Ets-1 effectively restored GSI in islets and Min6 cells previously exposed to high glucose over a 72 h period (Fig. 7c,d ), and increased insulin content (Fig. 7e,f) and insulin secretion under high glucose that was normalised to insulin content (Fig. 7g,h ). Together, these results identified Ets-1 as a mediator of glucotoxicity, as depicted in Fig. 7b . Chronic high glucose treatment stimulated Ets-1 expression, which directly downregulated PDX-1 expression and activity. Following the inhibition of PDX-1 expression and activity, insulin expression was downregulated, which resulted in pancreatic beta cell dysfunction.
Discussion
Glucotoxicity is a major determinant of causing beta cell failure in type 2 diabetes. The current studies demonstrate that Ets-1 mediates pancreatic beta cell dysfunction, linking glucotoxicity to type 2 diabetes. In db/db mice islets as well as in high glucose-treated Min6 cells and primary islets, Ets-1 expression was significantly increased. Using newly generated transgenic mice with overexpression of Ets-1 in pancreatic Luciferase activity/ β-gal activity beta cells, we demonstrate that Ets-1 excess induces glucose intolerance with defective insulin secretion. It is important to note that we obtained three transgenic lines exhibiting high (line 107), medium (line 123) and low (line 79) levels of Ets-1 expression in islets, which all displayed defective insulin secretion and PDX-1 expression (ESM Fig. 1d-h ). Thus, the observed effect in transgenic mice was due to expression levels of Ets-1 and was not explained by insertional mutagenesis, i.e. random incorporation of the transgene leading to inactivation of another gene. Histone modification has been shown to be important in pancreatic beta cell function [23] . Histone H4 acetylation is critical for activation of insulin gene expression [38] . However, it is unclear whether epigenetic modification is involved in manipulating Ets-1 expression in pancreatic beta cells treated with high glucose. We first analysed the promoter region of Ets-1, and found there were many CpG islands. However, 5-Aza-CdR, a specific inhibitor of DNA methylation, had no effect on Ets-1 expression (data not shown). Interestingly, the histone deacetylase inhibitor could upregulate Ets-1 expression in pancreatic beta cells. Meanwhile, high glucose increased histone H4 and H3 acetylation at the −1250 to −1054 regions of the Ets-1 promoter. These results clearly 
Mouse islets demonstrate the role of epigenetics in regulating Ets-1 transcription induced by high glucose.
It is important to recognise that Ets-1 overexpression caused a reduction in insulin content in pancreatic beta cells both in vivo and in cell-based models. It is therefore possible that decreased GSIS induced by Ets-1 was due to reduced insulin granule formation. Another possibility is that Ets-1 might impair insulin secretion from pancreatic beta cells. We found that overexpression of Ets-1 still decreased insulin secretion when normalised to insulin content. We also found that that overexpression of Ets-1 reduced ATP content under high glucose conditions (ESM Fig. 3a ) and GCK expression (ESM Fig. 3b,c) . Given ATP and GCK are major contributing factors involved in GSIS [39, 40] , reduction of ATP content and GCK expression could participate in Ets-1 impairing insulin secretion.
We identified, for the first time, PDX-1 as the downstream target of Ets-1 in mediating its regulatory effects on pancreatic beta cell function. We demonstrated that Ets-1 could bind to the promoter of Pdx-1 (the PH2 region) shared with FOXO1 and FOXA2 [18] . When Ets-1 was overexpressed in beta cells, the activity of FOXO1 binding to the PDX-1 promoter increased, but that of FOXA2 binding to the same site decreased, which was accompanied by the reduction of activity of the Pdx-1 promoter. Previous studies demonstrated that FOXO1 negatively regulated PDX-1 expression through decreasing Pdx-1 promoter activity while FOXA2 positively regulated PDX-1 expression through increasing Pdx-1 promoter activity [20, 41] . We also found that FOXO1 could interact with Ets-1 in pancreatic beta cells (Fig. 6a) . As shown here and previously, we propose that overexpression of Ets-1 enhanced FOXO1 occupying the area left vacant by FOXA2 on the Pdx-1 promoter, which resulted in inhibiting Pdx-1 promoter activity.
It should be noticed that Ets-1 did not bind to the Pdx-1 promoter in the control group, and interference of basal Ets-1 gene transcription did not affect PDX-1 expression (Fig. 5a,b) , which indicated that Ets-1 only inhibits PDX-1 expression under certain pathological situations such as hyperglycaemia. Similarly, the FOXO1 transcription factor demonstrated almost no binding to the Pdx-1 gene promoter, which was consistent with our previous results [41] . Thus, neither Ets-1 nor FOXO1 regulated PDX-1 expression by binding to the Pdx-1 promoter under basal situation.
The decrease of PDX-1 expression and DNA binding activities was implicated previously in chronic hyperglycaemiainduced beta cell dysfunction [17] . However, the potential mechanisms were unclear. Here, we established a connection between high glucose, Ets-1 elevation and reduction of PDX-1 expression. We described in detail the cause-and-effect relationship between the increased level of Ets-1 and decreased levels of PDX-1 in vivo and in vitro. High glucose increased the activity of Ets-1 binding to the Pdx-1 promoter (Fig. 6b) .
On the basis of the existing investigations, we speculated that Ets-1 was responsible for the reduction in PDX-1 expression under the hyperglycaemia condition.
In conclusion, our study demonstrates that chronic hyperglycaemia contributes to upregulation of Ets-1 expression by mediating hyperacetylation of histone H3 and H4 at the Ets-1 gene promoter, leading to reduction of PDX-1 expression, and finally to beta cell dysfunction. This process may be one of the molecular mechanisms responsible for glucotoxicity in beta cells.
